Skip to main content
Erschienen in:

05.08.2023 | Original Article

Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma

verfasst von: Kevin Tak-Pan Ng, Jiang Liu, Oscar Wai-Ho Yeung, Li Pang, Hoi Chung Shiu, Hui Liu, Xin Xiang Yang, Albert Chi-Yan Chan, Tiffany Cho-Lam Wong, Chung Mau Lo, Kwan Man

Erschienen in: Hepatology International | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Cytokines are key regulators of post-transplant inflammation responses which reconstitute post-transplant hepatic and systemic environments to influence the likelihood of tumor relapse. This study investigated the prognostic value of post-transplant cytokines on tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC).

Methods

A retrospective analysis was conducted in prospectively collected 150 adult HCC patients who received liver transplantation from 1997 to 2015. The post-transplant 41 inflammatory cytokines were quantified by multiplexing analysis and determined their prognostic value for predicting post-LT tumor recurrence by receiver operative characteristic analysis. A prediction model for post-LT tumor recurrence was generated by the logistic regression and internally validated Bootstrapping and compared with external prediction models.

Results

Post-transplant circulating CCL11, IFNα2, and IL17A cytokines were identified to be significant predictors of post-LT tumor recurrence and survival. A prediction score composed of the post-transplant 3-cytokine (P3C) signature, UCSF criteria, and pre-LT AFP was established. The P3C-UCSF-AFP score significantly predicted post-LT tumor recurrence and poor survival both in deceased donor liver transplantation (DDLT) and living donor liver transplantation (LDLT). The P3C-UCSF-AFP score was validated to significantly predict post-LT 2-year and 5-year tumor recurrence, outperforming the RETREAT score, French AFP model, up-to-seven, UCSF criteria, and Milan criteria. Importantly, the P3C-UCSF-AFP score could cost-effectively stratify high-risk recipients subjected to a refinement of post-recurrence survival.

Conclusion

The integrated P3C-UCSF-AFP score not only compensated for the pre-LT unpredictability and predicted post-LT tumor recurrence accurately, but also guided the clinical refinements of post-LT surveillance and therapeutic strategies in transplant oncology.

Graphical abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–217PubMedCrossRef Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–217PubMedCrossRef
3.
Zurück zum Zitat McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol. 2020;7(3):HEP26PubMedPubMedCentralCrossRef McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol. 2020;7(3):HEP26PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, et al. Post-transplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1143–1149PubMedCrossRef Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, et al. Post-transplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1143–1149PubMedCrossRef
5.
Zurück zum Zitat Liu Z, Liu Y, Zhang W, Hong Y, Meng J, Wang J, et al. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study. Hepatol Int. 2022;16(3):577–589PubMedCrossRef Liu Z, Liu Y, Zhang W, Hong Y, Meng J, Wang J, et al. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study. Hepatol Int. 2022;16(3):577–589PubMedCrossRef
6.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699PubMedCrossRef Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699PubMedCrossRef
7.
Zurück zum Zitat Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, et al. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int. 2020;33(7):697–712PubMedCrossRef Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, et al. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int. 2020;33(7):697–712PubMedCrossRef
8.
Zurück zum Zitat Liu H, Man K. New insights in mechanisms and therapeutics for short- and long-term impacts of hepatic ischemia reperfusion injury post liver transplantation. Int J Mol Sci. 2021;22(15):8210PubMedPubMedCentralCrossRef Liu H, Man K. New insights in mechanisms and therapeutics for short- and long-term impacts of hepatic ischemia reperfusion injury post liver transplantation. Int J Mol Sci. 2021;22(15):8210PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Li CX, Ling CC, Shao Y, Xu A, Li XC, Ng KT, et al. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol. 2016;65(5):944–952PubMedCrossRef Li CX, Ling CC, Shao Y, Xu A, Li XC, Ng KT, et al. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol. 2016;65(5):944–952PubMedCrossRef
10.
Zurück zum Zitat Ling CC, Ng KT, Shao Y, Geng W, Xiao JW, Liu H, et al. Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. J Hepatol. 2014;60(1):103–109PubMedCrossRef Ling CC, Ng KT, Shao Y, Geng W, Xiao JW, Liu H, et al. Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. J Hepatol. 2014;60(1):103–109PubMedCrossRef
11.
Zurück zum Zitat Man K, Lo CM, Xiao JW, Ng KT, Sun BS, Ng IO, et al. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg. 2008;247(6):1049–1057PubMedCrossRef Man K, Lo CM, Xiao JW, Ng KT, Sun BS, Ng IO, et al. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg. 2008;247(6):1049–1057PubMedCrossRef
12.
Zurück zum Zitat Liu J, Lo CM, Man K. Role of intrahepatic regional immunity in post-transplant cancer recurrence. Engineering. 2022;10:57–64CrossRef Liu J, Lo CM, Man K. Role of intrahepatic regional immunity in post-transplant cancer recurrence. Engineering. 2022;10:57–64CrossRef
13.
Zurück zum Zitat Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2007;94(1):78–86PubMedCrossRef Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2007;94(1):78–86PubMedCrossRef
14.
Zurück zum Zitat Akamatsu N, Kokudo N. Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. Hepatobiliary Surg Nutr. 2016;5(5):422–428PubMedPubMedCentralCrossRef Akamatsu N, Kokudo N. Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. Hepatobiliary Surg Nutr. 2016;5(5):422–428PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Kulik LM, Fisher RA, Rodrigo DR, Brown RS Jr, Freise CE, Shaked A, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant. 2012;12(11):2997–3007PubMedPubMedCentralCrossRef Kulik LM, Fisher RA, Rodrigo DR, Brown RS Jr, Freise CE, Shaked A, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant. 2012;12(11):2997–3007PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Man K. Recurrent malignancy: are we pushing the envelope? Liver Transpl. 2017;23(S1):S81–S84PubMedCrossRef Man K. Recurrent malignancy: are we pushing the envelope? Liver Transpl. 2017;23(S1):S81–S84PubMedCrossRef
17.
Zurück zum Zitat Sosa RA, Zarrinpar A, Rossetti M, Lassman CR, Naini BV, Datta N, et al. Early cytokine signatures of ischemia/reperfusion injury in human orthotopic liver transplantation. JCI Insight. 2016;1(20):e89679PubMedPubMedCentralCrossRef Sosa RA, Zarrinpar A, Rossetti M, Lassman CR, Naini BV, Datta N, et al. Early cytokine signatures of ischemia/reperfusion injury in human orthotopic liver transplantation. JCI Insight. 2016;1(20):e89679PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Pang L, Ng KT, Liu J, Yeung WO, Zhu J, Chiu TS, et al. Plasmacytoid dendritic cells recruited by HIF-1alpha/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. Cancer Lett. 2021;522:80–92PubMedCrossRef Pang L, Ng KT, Liu J, Yeung WO, Zhu J, Chiu TS, et al. Plasmacytoid dendritic cells recruited by HIF-1alpha/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. Cancer Lett. 2021;522:80–92PubMedCrossRef
20.
Zurück zum Zitat Sun R, Zhang L, Yang Z, Zhou K, Tang H, Zhao W, et al. Liver transplantation for hepatocellular carcinoma: a prognostic model incorporating pretransplant inflammatory cytokines. Cytokine. 2022;153:155847PubMedCrossRef Sun R, Zhang L, Yang Z, Zhou K, Tang H, Zhao W, et al. Liver transplantation for hepatocellular carcinoma: a prognostic model incorporating pretransplant inflammatory cytokines. Cytokine. 2022;153:155847PubMedCrossRef
21.
Zurück zum Zitat Hwang W, Lee J. Pathophysiologic Implications of cytokines secretion during liver transplantation surgery. Int J Med Sci. 2018;15(14):1737–1745PubMedPubMedCentralCrossRef Hwang W, Lee J. Pathophysiologic Implications of cytokines secretion during liver transplantation surgery. Int J Med Sci. 2018;15(14):1737–1745PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Wong TC, Fung JYY, Cui TYS, Sin SL, Ma KW, She BWH, et al. The risk of going small: lowering GRWR and overcoming small-for-size syndrome in adult living donor liver transplantation. Ann Surg. 2021;274(6):e1260–e1268PubMedCrossRef Wong TC, Fung JYY, Cui TYS, Sin SL, Ma KW, She BWH, et al. The risk of going small: lowering GRWR and overcoming small-for-size syndrome in adult living donor liver transplantation. Ann Surg. 2021;274(6):e1260–e1268PubMedCrossRef
23.
Zurück zum Zitat Wong CS, Lee WC, Jenq CC, Tian YC, Chang MY, Lin CY, et al. Scoring short-term mortality after liver transplantation. Liver Transpl. 2010;16(2):138–146PubMedCrossRef Wong CS, Lee WC, Jenq CC, Tian YC, Chang MY, Lin CY, et al. Scoring short-term mortality after liver transplantation. Liver Transpl. 2010;16(2):138–146PubMedCrossRef
24.
25.
Zurück zum Zitat Toniutto PFE, Fumolo E, Bitetto D. Risk factors for hepatocellular carcinoma recurrence after liver transplantation. Hepatoma Res. 2020;6:50 Toniutto PFE, Fumolo E, Bitetto D. Risk factors for hepatocellular carcinoma recurrence after liver transplantation. Hepatoma Res. 2020;6:50
26.
Zurück zum Zitat Elkomos BE, Abdo M, Mamdouh R, Abdelaal A. Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis. Hepatol Int. 2023;17(1):18–37PubMedCrossRef Elkomos BE, Abdo M, Mamdouh R, Abdelaal A. Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis. Hepatol Int. 2023;17(1):18–37PubMedCrossRef
27.
Zurück zum Zitat Boteon Y, Flores Carvalho MA, Panconesi R, Muiesan P, Schlegel A. Preventing tumour recurrence after liver transplantation: the role of machine perfusion. Int J Mol Sci. 2020;21(16):5791PubMedPubMedCentralCrossRef Boteon Y, Flores Carvalho MA, Panconesi R, Muiesan P, Schlegel A. Preventing tumour recurrence after liver transplantation: the role of machine perfusion. Int J Mol Sci. 2020;21(16):5791PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Shih KC, Man K. Small-for-size liver graft injury–impact on tumor behavior. Transplant Rev (Orlando). 2010;24(1):1–10PubMedCrossRef Shih KC, Man K. Small-for-size liver graft injury–impact on tumor behavior. Transplant Rev (Orlando). 2010;24(1):1–10PubMedCrossRef
29.
Zurück zum Zitat Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2020;20(2):333–347PubMedCrossRef Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2020;20(2):333–347PubMedCrossRef
30.
Zurück zum Zitat Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157(9):779–788PubMedPubMedCentral Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157(9):779–788PubMedPubMedCentral
31.
Zurück zum Zitat Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, et al. Surveillance for HCC after liver transplantation: increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020;104(10):2105–2112PubMedCrossRef Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, et al. Surveillance for HCC after liver transplantation: increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020;104(10):2105–2112PubMedCrossRef
32.
Zurück zum Zitat Roberts JP. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2005;2:S45–S46CrossRef Roberts JP. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2005;2:S45–S46CrossRef
33.
Zurück zum Zitat Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3(4):493–500PubMedPubMedCentralCrossRef Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3(4):493–500PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Aggarwal A, Te HS, Verna EC, Desai AP. A national survey of hepatocellular carcinoma surveillance practices following liver transplantation. Transplant Direct. 2021;7(1):e638PubMedCrossRef Aggarwal A, Te HS, Verna EC, Desai AP. A national survey of hepatocellular carcinoma surveillance practices following liver transplantation. Transplant Direct. 2021;7(1):e638PubMedCrossRef
35.
Zurück zum Zitat Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol. 2020;115(10):1642–1649PubMedPubMedCentralCrossRef Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol. 2020;115(10):1642–1649PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Agarwal PD, Lucey MR. Management of hepatocellular carcinoma recurrence after liver transplantation. Ann Hepatol. 2022;27(1):100654PubMedCrossRef Agarwal PD, Lucey MR. Management of hepatocellular carcinoma recurrence after liver transplantation. Ann Hepatol. 2022;27(1):100654PubMedCrossRef
37.
Zurück zum Zitat Wang R, Huang K. CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL2 and TGFbeta by CD4+ T cells via the STAT5 signaling pathway. Mol Med Rep. 2020;21(6):2522–2532PubMedPubMedCentral Wang R, Huang K. CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL2 and TGFbeta by CD4+ T cells via the STAT5 signaling pathway. Mol Med Rep. 2020;21(6):2522–2532PubMedPubMedCentral
38.
Zurück zum Zitat Taleb K, Auffray C, Villefroy P, Pereira A, Hosmalin A, Gaudry M, et al. Chronic type I IFN is sufficient to promote immunosuppression through accumulation of myeloid-derived suppressor cells. J Immunol. 2017;198(3):1156–1163PubMedCrossRef Taleb K, Auffray C, Villefroy P, Pereira A, Hosmalin A, Gaudry M, et al. Chronic type I IFN is sufficient to promote immunosuppression through accumulation of myeloid-derived suppressor cells. J Immunol. 2017;198(3):1156–1163PubMedCrossRef
39.
Zurück zum Zitat Pang L, Yeung OWH, Ng KTP, Liu H, Zhu J, Liu J, et al. Postoperative plasmacytoid dendritic cells secrete IFN-alpha to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence. Cancer Res. 2022. Pang L, Yeung OWH, Ng KTP, Liu H, Zhu J, Liu J, et al. Postoperative plasmacytoid dendritic cells secrete IFN-alpha to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence. Cancer Res. 2022.
40.
Zurück zum Zitat Itoh S, Kimura N, Axtell RC, Velotta JB, Gong Y, Wang X, et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion. Circulation. 2011;124(11 Suppl):S187–S196PubMed Itoh S, Kimura N, Axtell RC, Velotta JB, Gong Y, Wang X, et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion. Circulation. 2011;124(11 Suppl):S187–S196PubMed
41.
Zurück zum Zitat Zhou Y, Yang X, Zhang H, Jiang J. The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats. Transplantation. 2015;99(6):1126–1131PubMedCrossRef Zhou Y, Yang X, Zhang H, Jiang J. The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats. Transplantation. 2015;99(6):1126–1131PubMedCrossRef
42.
Zurück zum Zitat Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86PubMedPubMedCentralCrossRef Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Luo Y, Teng F, Fu H, Ding GS. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol. 2022;14(1):163–180PubMedPubMedCentralCrossRef Luo Y, Teng F, Fu H, Ding GS. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol. 2022;14(1):163–180PubMedPubMedCentralCrossRef
Metadaten
Titel
Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma
verfasst von
Kevin Tak-Pan Ng
Jiang Liu
Oscar Wai-Ho Yeung
Li Pang
Hoi Chung Shiu
Hui Liu
Xin Xiang Yang
Albert Chi-Yan Chan
Tiffany Cho-Lam Wong
Chung Mau Lo
Kwan Man
Publikationsdatum
05.08.2023
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 6/2023
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10566-1

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Koronare Herzkrankheit: Das waren die Top-Studien 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.